Steve Worobel <br />Portfolio Research Analyst
Steve Worobel
Portfolio Research Analyst

By focusing on small- and mid-cap stocks we seek to discover companies whose earnings growth prospects exceed the market’s expectations.  These provide great investment opportunities for our clients.

Multi-Cap Core Equity

The 1919 Investment Counsel (1919ic) Multi-Cap Core Equity Department's strategy is diversified with a concentration in U.S. small- and mid-cap stocks. Our primary goal is to add value through our proprietary research, judgment, and discipline rather than replicating an index. The style is complementary to the 1919ic core equity strategy.

The bias towards small- and mid-cap companies underscores our belief that to achieve long-term capital appreciation one must invest in companies that will offer superior growth rates over the long term. There is no restriction on company size, giving us the flexibility to hold names that have crossed the threshold from mid- to large-cap, yet continue to meet our investment criteria.

Our Approach

The team analyzes demographic and regional trends to determine the earnings potential of particular companies. Using the same analysis we then seek to identify investment themes to take advantage of long-term secular trends in the economy. In order to maximize potential returns, we will at times overweight or underweight certain sectors.

Key Differentiators

  • Invest in stocks for the long term
  • Proprietary bottom-up fundamental independent research
  • Significant sector concentrations 
  • Do not mirror any index
  • Low turnover portfolios

All investments involve risk and there is no guarantee investment objectives will be met.

Baltimore, MD

100 International Drive
5th Floor
Baltimore, MD 21202
(844) 200-1919

Cincinnati, OH

600 Vine Street
Suite 2000
Cincinnati, OH 45202
(800) 654-5777

New York, NY

640 Fifth Avenue
9th Floor
New York, NY 10019
(866) 566-0425

Philadelphia, PA

Two Logan Square
Suite 1850
Philadelphia, PA 19103
(800) 806-2732

What We're Thinking

Fighting cancer with the immune system: Hope or hype?

The United States is spending more than $125 billion on cancer care each year, but our expensive modern medicine has plenty of room for improvement as only 66% of cancer patients live longer than five years, according to the National Institutes of Health (NIH). Investors are beginning to take notic »